Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myoinositol, Chromium, or L-arginine with Letrozole for PCOS
NCT06405243Phase 3Not yet recruiting
- Sponsor
- Beni Suef University
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in polycystic ovary syndrome (PCOS) and infertility comparing Myoinositol + Letrozole, Chromium + Letrozole and L-arginine + Letrozole (3 arms). Primary endpoint: Ovulation at 3 months. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
myo-inositolchromiumarginine
03
Conditions
polycystic ovary syndrome (PCOS)infertility
Beyond the preview
Go deeper on NCT06405243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06405243.